Why the Future of Cancer Care Depends on Localizing CAR-T Cell Production
Summary
The article discusses advancements in cancer treatment, specifically CAR-T therapy, which is a personalized treatment for aggressive blood cancers like leukemia. King Faisal Specialist Hospital in Saudi Arabia focuses on localizing CAR-T production to reduce costs and improve accessibility for patients. By manufacturing CAR-T locally, they have significantly reduced treatment costs and production time, offering timely access to patients.Key Facts
- CAR-T therapy is a treatment that uses the patient's own immune cells to fight cancer.
- Traditional CAR-T production is costly, often over $300,000 per patient, and involves complex logistics.
- King Faisal Specialist Hospital (KFSHRC) built a local CAR-T production facility in Saudi Arabia.
- Local production reduced costs by 80%, bringing it down to about $67,000 per patient.
- The facility at KFSHRC can produce 2,400 doses a year, aiming to meet national demand.
- Localizing CAR-T production allows patients quicker access to treatment.
- Since 2020, KFSHRC has treated over 200 patients with CAR-T therapies.
- The first patient treated with locally produced CAR-T cells achieved remission after a single dose.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
